H.C. Wainwright Starts Oncothyreon (ONTY) at Buy
Get Alerts ONTY Hot Sheet
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
H.C. Wainwright initiated coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and a price target of $4.00.
Analyst Reni Benjamin said, "Oncothyreon’s biotechnology franchise is comprised of diverse set of therapeutics including ONT-380, a potent and highly specific tyrosine kinase inhibitor targeting HER2, as well as ONT-10, an immunotherapy vaccine targeting MUC1. Additionally, the company’s recent acquisition of Alpine Biosciences brings a novel drug-delivery platform in-house, which we believe could be utilized to generate multiple therapeutic candidates in a wide variety of indications, including orphan diseases. Given the company’s burgeoning pipeline, ability to secure multiple partnerships and strong cash position of approximately $91.2 MM (pro forma), which we expect to last till 2H16, we believe Oncothyreon represents an undervalued player with significant upside for the long-term investor."
For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.
Shares of Oncothyreon closed at $1.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Malaysia Airports Holdings Bhd (MAHB:MK) (MYPRF) to Neutral
- H.C. Wainwright Reiterates Sell Rating on Hut 8 Mining Corp. (HUT)
- MarketWise Inc. (MKTW) PT Lowered to $2 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!